Trials / Completed
CompletedNCT00083889
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon-alfa | 3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity |
| DRUG | SU011248 | 50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2004-06-04
- Last updated
- 2010-01-26
- Results posted
- 2009-12-10
Locations
123 sites across 11 countries: United States, Australia, Brazil, Canada, France, Germany, Italy, Poland, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00083889. Inclusion in this directory is not an endorsement.